4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded by Chardan Capital to “Strong-Buy” Rating

Chardan Capital upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

Several other research analysts also recently commented on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group restated a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $10.07 on Tuesday. 4D Molecular Therapeutics has a 1 year low of $4.30 and a 1 year high of $14.00. The business’s 50 day moving average price is $10.55 and its 200-day moving average price is $9.64. The firm has a market capitalization of $526.42 million, a price-to-earnings ratio of -3.92 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. On average, sell-side analysts expect that 4D Molecular Therapeutics will post -3.8 earnings per share for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This represents a 53.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 184,811 shares of company stock worth $2,075,906. Insiders own 7.90% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Bank of America Corp DE boosted its position in shares of 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock worth $9,070,000 after buying an additional 141,582 shares during the period. Janus Henderson Group PLC raised its holdings in shares of 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares during the period. Exome Asset Management LLC acquired a new position in 4D Molecular Therapeutics during the 1st quarter worth about $1,216,000. Renaissance Technologies LLC lifted its stake in 4D Molecular Therapeutics by 12.7% during the 1st quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock worth $5,384,000 after acquiring an additional 65,365 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after acquiring an additional 1,050 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.